Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Cybin Inc. CLXPF

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time.Company is advancing two new therapeutic candidates with enhanced, improved properties.Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a … Continue reading

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, … Continue reading

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the … Continue reading

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference. Drysdale’s presentation is … Continue reading

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at 2021 Emerging Growth Virtual Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the M Vest and Maxim Group 2021 Emerging Growth … Continue reading

Posted in Cybin Inc. CLXPF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Stifel GMP Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Stifel GMP Health Care Conference – Health Care … Continue reading

Posted in Cybin Inc. CLXPF, MissionIRNewsBreaks | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand

Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offeringBurgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments.Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin (NEO: CYBN) … Continue reading

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Commences Trading on the OTCQB(R) Venture Market

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its shares have commenced trading on the OTCQB(R) Venture Market under the symbol “CLXPF.” “With the commencement of trading on the OTCQB, Cybin has … Continue reading

Posted in Cybin Inc. CLXPF, MissionIRNewsBreaks | Leave a comment

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Newly Acquired Subsidiary Achieves Earn-Out Milestone —Successful Synthesis of Multiple Tryptamine Derivatives

Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with CybinAdelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health spaceAcquisition results in Cybin obtaining extensive intellectual property portfolio and product … Continue reading

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Commence Trading on the OTCQB Venture Market

Cybin (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB(R) Venture Market. Cybin will commence trading on the OTCQB under the symbol “CLXPF” at … Continue reading

Posted in Cybin Inc. CLXPF, MissionIRNewsBreaks | Leave a comment